BioNTech
An der Goldgrube 12
Mainz
D-55131
Germany
148 articles with BioNTech
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
-
The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month, once fully operational, the company said.
-
Only days after saying it expects to have key data from its Phase III clinical trial of its COVID-19 vaccine in October, Germany’s BioNTech received a grant of up to €375 million from the German Federal Ministry of Education and Research.
-
In a weekend interview on CBS’ “Face the Nation,” Albert Bourla, chief executive officer of Pfizer indicated they may have key data from its Phase III trial of the vaccine to the U.S. Food and Drug Administration by the end of October.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
-
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial
9/12/2020
Pfizer Inc. and BioNTech SE announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
-
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
-
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
9/9/2020
The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval
-
Pfizer and BioNTech Announce Data From Preclinical Studies of mRNA-Based Vaccine Candidate Against COVID-19
9/9/2020
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
-
The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Moderna, Novavax, Pfizer, Merck and Sanofi all signed the pledge promising to ensure that any vaccine put forth by one or more of the companies meets the rigorous standards for approval.
-
Biopharma Leaders Unite to Stand with Science
9/8/2020
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
-
Clinical Catch-Up: August 17-21
8/24/2020
It was a relatively quiet week for clinical trial news. Here’s a look. -
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
8/21/2020
In a Phase 1 study in the U.S., at 7 days after a second dose of 30 μg, BNT162b2 elicited SARS-CoV-2–neutralizing geometric mean titers (GMTs) in younger adults (18-55 years of age) that were 3.8 times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 times the GMT of the same panel, demonstrating strong immunogenicity in younger and older adult
-
Today’s data describes key safety and immunogenicity data from the U.S. Phase I study for BNT162b.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
-
BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
8/11/2020
Pivotal Phase 2b/3 trial for BNT162 vaccine program against COVID-19 initiated with first clinical results expected as early as October 2020
-
Clinical Catch-Up: August 3-7
8/10/2020
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look. -
BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020
8/6/2020
BioNTech SE will announce its financial results for the second quarter 2020 on Tuesday, August 11th, 2020.